Show simple item record

Direktni oralni antikoagulantni lekovi u profilaksi i terapiji tromboembolijskih bolesti

dc.creatorTomić, Milan
dc.creatorNovaković, Aleksandra
dc.creatorMilojević, Predrag
dc.creatorNenezić, Dragoslav
dc.creatorStojanović, Ivan
dc.creatorGajin, Predrag
dc.date.accessioned2019-09-02T12:00:50Z
dc.date.available2019-09-02T12:00:50Z
dc.date.issued2017
dc.identifier.issn0350-1221
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/2936
dc.description.abstractMore than 50 years ago, vitamin K antagonists were the only available oral anticoagulants. Since their application involves a number of limitations, it was necessary to develop new oral anticoagulant drugs and introduce them into clinical practice. These drugs have many advantages over vitamin K antagonists, including rapid onset/offset, a small number of interactions with other drugs and food, simplified dosing and predictable pharmacokinetics, eliminating the need for daily laboratory monitoring. In addition, new oral anticoagulant drugs act selectively on a single coagulation factor. Currently, the following drugs are approved for use: direct thrombin inhibitor, dabigatran etexilate, direct factor Xa inhibitor, rivaroxaban, apixaban and edoxaban. Dabigatran etexilate and apixaban are approved for the primary prevention of venous thromboembolism in adult patients undergoing elective surgery of total hip or knee replacement, while in addition to these anticoagulants edoxaban is approved for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. For the treatment and prevention of recurrent deep vein thrombosis dabigatran etexilate, rivaroxaban and edoxaban are approved. In addition, rivaroxaban is approved for the secondary prevention of atherothrombotic events in patients with acute coronary syndrome.en
dc.description.abstractViše od 50 godina, antagonisti vitamina K bili su jedini dostupni oralni antikoagulantni lekovi. S obzirom na to da njihova primena podrazumeva brojna ograničenja, bilo je neophodno razviti i uvesti u kliničku praksu nove oralne antikoagulantne lekove. Ovi lekovi imaju brojne prednosti u poređenju s antagonistima vitamina K, koje uključuju brz početak i prestanak dejstva, mali broj interakcija s drugim lekovima i hranom, pojednostavljen način doziranja, kao i predvidivu farmakokinetiku, čime se eliminiše potreba za svakodnevnim laboratorijskim praćenjem. Osim toga, novi oralni antikoagulantni lekovi deluju selektivno samo na jedan faktor koagulacije. Trenutno su odobreni za upotrebu direktni inhibitor trombina, dabigatran eteksilat, kao i direktni inhibitori faktora Xa, rivaroksaban, edoksaban i apiksaban. Dabigatran eteksilat i apiksaban odobreni su za primarnu prevenciju venske tromboembolije kod odraslih pacijenata koji se podvrgavaju elektivnom hirurškom zahvatu totalne zamene kuka ili kolena, dok je za prevenciju moždanog udara i sistemske embolije kod odraslih pacijenata sa nevalvularnom atrijalnom fibrilacijom, pored navedenih antikoagulantnih lekova, odobren i edoksaban. Za terapiju i prevenciju rekurentne duboke venske tromboze odobreni su dabigatran eteksilat, rivaroksaban i edoksaban. Osim toga, rivaroksaban je odobren i za sekundarnu prevenciju aterotrombotičkih događaja nakon akutnog koronarnog sindroma.sr
dc.publisherSrpsko lekarsko društvo - Okružna podružnica Kragujevac, Kragujevac
dc.rightsopenAccess
dc.sourceMedicinski časopis
dc.subjectanticoagulantsen
dc.subjectthrombinen
dc.subjectfactor Xaen
dc.subjectfactor IXaen
dc.subjectthrombosisen
dc.subjectantikoagulansisr
dc.subjecttrombinsr
dc.subjectfaktor Xasr
dc.subjectfaktor IXasr
dc.subjecttrombozasr
dc.titleDirect oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseasesen
dc.titleDirektni oralni antikoagulantni lekovi u profilaksi i terapiji tromboembolijskih bolestisr
dc.typearticle
dc.rights.licenseARR
dcterms.abstractМилојевић, Предраг; Томић, Милан; Гајин, Предраг; Стојановић, Иван; Новаковић, Aлександра; Ненезић, Драгослав; Директни орални антикоагулантни лекови у профилакси и терапији тромбоемболијских болести; Директни орални антикоагулантни лекови у профилакси и терапији тромбоемболијских болести;
dc.citation.volume51
dc.citation.issue3
dc.citation.spage89
dc.citation.epage97
dc.citation.other51(3): 89-97
dc.citation.rankM52
dc.identifier.doi10.5937/mckg51-15563
dc.identifier.scopus2-s2.0-85042776584
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs//bitstream/id/1549/2934.pdf
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record